Abstract:The absence of T‐cell death‐associated gene 51 (TDAG51) in mice results in late‐onset insulin resistance (IR), obesity and hepatic steatosis. In support of these findings, mice fed a high fat diet, which leads to IR and obesity, as well as the leptin‐deficient mouse model, a well‐established genetic model of type 2 diabetes and obesity, show significantly diminished hepatic TDAG51 protein levels. Here we report that hepatic TDAG51 protein levels are reduced in multiple mouse models of liver injury and in liver biopsies from patients with non‐alcoholic steatohepatitis. Given that hepatic TDAG51 protein levels decrease under conditions of fatty liver and correlate with IR, we investigated whether restoring hepatic TDAG51 protein levels would reverse hepatic IR. Hepatic expression of a TDAG51‐GFP fusion protein was increased via a liver‐specific adeno‐associated virus (AAV) in both TDAG51 knockout and leptin‐deficient mice. Restoration of hepatic TDAG51 protein increased insulin sensitivity and reduced weight gain compared to mice injected with a control AAV vector encoding only GFP. Specifically, TDAG51 knockout mice expressing ectopic TDAG51 demonstrated: 1) improved Akt473 phosphorylation, 2) reduced expression of diacylglycerol O‐acyltransferase, which catalyzes the final step in triglyceride biosynthesis, and 3) reduced expression of the SREBP‐1c target genes, fatty acid synthase and stearoyl‐CoA desaturase‐1. These findings demonstrate that restoring hepatic TDAG51 in mouse models of metabolic disease and fatty liver improves hepatic insulin signaling and reduces weight gain. However, this protective effect is lost over time, correlates with fatty liver progression and is accompanied by diminished hepatic TDAG51 protein stability. Taken together, these studies suggest that hepatic TDAG51 is an important factor that mediates insulin signaling and weight gain. Future studies aimed at increasing hepatic TDAG51 protein levels and/or stability may represent a new therapeutic opportunity for the amelioration of obesity and augmentation of insulin sensitivity in non‐alcoholic fatty liver disease. Support or Funding Information R.C.A is supported by grants from the Heart and Stroke Foundation of Ontario and the Canadian Institutes of Health Research. Financial support from St. Joseph's Healthcare Hamilton is also acknowledged. R.C.A. is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Amgen Canada Research Chair in Nephrology. K.N.M acknowledges financial support from the William R. Hummel Homocystinuria Research Fund and holds the Ehst‐Hummel‐Kaufmann Family Endowed Chair in Inherited Metabolic Disease. G.R.S is supported by a Canada Research Chair in Metabolism and Obesity, the J. Bruce Duncan Endowed Chair in Metabolic Diseases and grants from the Canadian Institutes of Health Research and Diabetes Canada. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Restoration of the ER stress response protein TDAG51 in hepatocytes mitigates NAFLD in mice

Restoration of hepatic TDAG51 expression improves insulin signaling and reduces weight gain in mouse models of non‐alcoholic fatty liver disease

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Angiotensinogen in Hepatocytes Contributes to Western Diet-Induced Liver Steatosis

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Estrogen receptor activation remodels TEAD1 gene expression to alleviate hepatic steatosis

HtrA2/Omi mitigates NAFLD in high-fat-fed mice by ameliorating mitochondrial dysfunction and restoring autophagic flux

Treatment With Ppar Delta Agonist Alleviates Non-Alcoholic Fatty Liver Disease By Modulating Glucose And Fatty Acid Metabolic Enzymes In A Rat Model

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

Eliciting the Mitochondrial Unfolded Protein Response by Nicotinamide Adenine Dinucleotide Repletion Reverses Fatty Liver Disease in Mice

Adeno-Associated Virus-Mediated Knockdown Of Slc16a11 Improves Glucose Tolerance And Hepatic Insulin Signaling In High Fat Diet-Fed Mice

Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis

Hepatocyte TMEM16A Deletion Retards NAFLD Progression by Ameliorating Hepatic Glucose Metabolic Disorder

1599-P: Regulation of Mitochondrial Dynamics Ameliorates Hepatic Steatosis through TFEB Activation

Targeting Hepatic TRAF1-ASK1 Signaling to Improve Inflammation, Insulin Resistance, and Hepatic Steatosis.

A-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARa Pathway

Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice

Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction

The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway

Systemic Overexpression of GDF5 in Adipocytes but Not Hepatocytes Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice